Literature DB >> 27885265

The disparate origins of ovarian cancers: pathogenesis and prevention strategies.

Anthony N Karnezis1, Kathleen R Cho2, C Blake Gilks1, Celeste Leigh Pearce3, David G Huntsman1.   

Abstract

Ovarian cancer is the fifth cause of cancer-related death in women and comprises a histologically and genetically broad range of tumours, including those of epithelial, sex cord-stromal and germ cell origin. Recent evidence indicates that high-grade serous ovarian carcinoma, clear cell carcinoma and endometrioid carcinoma primarily arise from tissues that are not normally present in the ovary. These histogenetic pathways are informing risk-reduction strategies for the prevention of ovarian and ovary-associated cancers and have highlighted the importance of the seemingly unique ovarian microenvironment.

Entities:  

Mesh：

Year:  2016        PMID： 27885265     DOI： 10.1038/nrc.2016.113

Source DB:  PubMed          Journal:  Nat Rev Cancer        ISSN： 1474-175X            Impact factor:   60.716


  158 in total

1.  Reproductive and hormonal factors, and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers: results from the International BRCA1/2 Carrier Cohort Study.

Authors:  Antonis C Antoniou; Matti Rookus; Nadine Andrieu; Richard Brohet; Jenny Chang-Claude; Susan Peock; Margaret Cook; D Gareth Evans; Rosalind Eeles; Catherine Nogues; Laurence Faivre; Paul Gesta; Flora E van Leeuwen; Margreet G E M Ausems; Ana Osorio; Trinidad Caldes; Jacques Simard; Jan Lubinski; Anne-Marie Gerdes; Edith Olah; Christine Fürhauser; Hakan Olsson; Brita Arver; Paolo Radice; Douglas F Easton; David E Goldgar
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-02-03       Impact factor: 4.254

Review 2.  The distinguishing cellular and molecular features of the endometriotic ovarian cyst: from pathophysiology to the potential endometrioma-mediated damage to the ovary.

Authors:  A M Sanchez; P Viganò; E Somigliana; P Panina-Bordignon; P Vercellini; M Candiani
Journal:  Hum Reprod Update       Date:  2013-10-14       Impact factor: 15.610

3.  Emerging roles for PAX8 in ovarian cancer and endosalpingeal development.

Authors:  Nathan J Bowen; Sanjay Logani; Erin B Dickerson; Laura B Kapa; Mariam Akhtar; Benedict B Benigno; John F McDonald
Journal:  Gynecol Oncol       Date:  2006-10-24       Impact factor: 5.482

4.  Recurrent somatic DICER1 mutations in nonepithelial ovarian cancers.

Authors:  Alireza Heravi-Moussavi; Michael S Anglesio; S-W Grace Cheng; Janine Senz; Winnie Yang; Leah Prentice; Anthony P Fejes; Christine Chow; Alicia Tone; Steve E Kalloger; Nancy Hamel; Andrew Roth; Gavin Ha; Adrian N C Wan; Sarah Maines-Bandiera; Clara Salamanca; Barbara Pasini; Blaise A Clarke; Anna F Lee; Cheng-Han Lee; Chengquan Zhao; Robert H Young; Samuel A Aparicio; Poul H B Sorensen; Michelle M M Woo; Niki Boyd; Steven J M Jones; Martin Hirst; Marco A Marra; Blake Gilks; Sohrab P Shah; William D Foulkes; Gregg B Morin; David G Huntsman
Journal:  N Engl J Med       Date:  2011-12-21       Impact factor: 91.245

5.  Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma.

Authors:  Siân Jones; Tian-Li Wang; Ie-Ming Shih; Tsui-Lien Mao; Kentaro Nakayama; Richard Roden; Ruth Glas; Dennis Slamon; Luis A Diaz; Bert Vogelstein; Kenneth W Kinzler; Victor E Velculescu; Nickolas Papadopoulos
Journal:  Science       Date:  2010-09-08       Impact factor: 47.728

6.  The murine winged-helix transcription factor Foxl2 is required for granulosa cell differentiation and ovary maintenance.

Authors:  Dirk Schmidt; Catherine E Ovitt; Katrin Anlag; Sandra Fehsenfeld; Lars Gredsted; Anna-Corina Treier; Mathias Treier
Journal:  Development       Date:  2004-01-21       Impact factor: 6.868

7.  A quantitative assessment of oral contraceptive use and risk of ovarian cancer.

Authors:  S E Hankinson; G A Colditz; D J Hunter; T L Spencer; B Rosner; M J Stampfer
Journal:  Obstet Gynecol       Date:  1992-10       Impact factor: 7.661

8.  Loss of Wnt4 and Foxl2 leads to female-to-male sex reversal extending to germ cells.

Authors:  Chris Ottolenghi; Emanuele Pelosi; Joseph Tran; Maria Colombino; Eric Douglass; Timur Nedorezov; Antonio Cao; Antonino Forabosco; David Schlessinger
Journal:  Hum Mol Genet       Date:  2007-08-29       Impact factor: 6.150

9.  Ovarian carcinoma arising in atypical endometriosis.

Authors:  U M Moll; J C Chumas; E Chalas; W J Mann
Journal:  Obstet Gynecol       Date:  1990-03       Impact factor: 7.661

10.  Clinicopathologic characteristics of granulosa cell tumors of the ovary: a multicenter retrospective study.

Authors:  In Ho Lee; Chel Hun Choi; Dae Gy Hong; Jae Yun Song; Young Jae Kim; Kyung Tai Kim; Kyu Wan Lee; Il Soo Park; Duk Soo Bae; Tae Jin Kim
Journal:  J Gynecol Oncol       Date:  2011-09-28       Impact factor: 4.401
View more
  98 in total

Review 1.  Preclinical Models of Ovarian Cancer: Pathogenesis, Problems, and Implications for Prevention.

Authors:  Anthony N Karnezis; Kathleen R Cho
Journal:  Clin Obstet Gynecol       Date:  2017-12       Impact factor: 2.190

2.  Recurrent ubiquitin B silencing in gynecological cancers establishes dependence on ubiquitin C.

Authors:  Alexia T Kedves; Scott Gleim; Xiaoyou Liang; Dennis M Bonal; Frederic Sigoillot; Fred Harbinski; Sneha Sanghavi; Christina Benander; Elizabeth George; Prafulla C Gokhale; Quang-De Nguyen; Paul T Kirschmeier; Robert J Distel; Jeremy Jenkins; Michael S Goldberg; William C Forrester
Journal:  J Clin Invest       Date:  2017-11-13       Impact factor: 14.808

Review 3.  Endometriosis-associated ovarian cancer occurs early during follow-up of endometrial cysts.

Authors:  Kosuke Murakami; Yasushi Kotani; Reona Shiro; Hisamitsu Takaya; Hidekatsu Nakai; Noriomi Matsumura
Journal:  Int J Clin Oncol       Date:  2019-08-31       Impact factor: 3.402

4.  Invited Commentary: Relationship Between Ovulation and Markers of Systemic Inflammation Versus Markers of Localized Inflammation.

Authors:  Joellen M Schildkraut
Journal:  Am J Epidemiol       Date:  2020-07-01       Impact factor: 4.897

5.  Pathways to Genome-targeted Therapies in Serous Ovarian Cancer.

Authors:  Joshua Axelrod; Joe Delaney
Journal:  J Nat Sci       Date:  2017-07

6.  A thiazole-derived oridonin analogue exhibits antitumor activity by directly and allosterically inhibiting STAT3.

Authors:  Xiaofei Shen; Lin Zhao; Peihao Chen; Yanqiu Gong; Dingdong Liu; Xia Zhang; Lunzhi Dai; Qingxiang Sun; Jizhong Lou; Zhong Jin; Baohua Zhang; Dawen Niu; Ceshi Chen; Xiangbing Qi; Da Jia
Journal:  J Biol Chem       Date:  2019-10-08       Impact factor: 5.157

7.  MicroRNA-654-5p suppresses ovarian cancer development impacting on MYC, WNT and AKT pathways.

Authors:  Blanca Majem; Alfonso Parrilla; Carlos Jiménez; Leticia Suárez-Cabrera; Marta Barber; Andrea Marín; Josep Castellví; Gabriel Tamayo; Gema Moreno-Bueno; Jordi Ponce; Xavier Matias-Guiu; Francesc Alameda; Ignacio Romero; José Luis Sánchez; Asunción Pérez-Benavente; Sebastián Moran; Manel Esteller; Jaume Reventós; Marina Rigau; Antonio Gil-Moreno; Miguel F Segura; Anna Santamaría
Journal:  Oncogene       Date:  2019-07-05       Impact factor: 9.867

Review 8.  Fallopian tube initiation of high grade serous ovarian cancer and ovarian metastasis: Mechanisms and therapeutic implications.

Authors:  Tova M Bergsten; Joanna E Burdette; Matthew Dean
Journal:  Cancer Lett       Date:  2020-02-15       Impact factor: 8.679

Review 9.  Developmental Programming of Ovarian Functions and Dysfunctions.

Authors:  Muraly Puttabyatappa; Vasantha Padmanabhan
Journal:  Vitam Horm       Date:  2018-02-22       Impact factor: 3.421

10.  Increase of fallopian tube and decrease of ovarian carcinoma: fact or fake?

Authors:  Anne Kathrin Höhn; Sabine Klagges; Albrecht Gläser; Sabine Taubenheim; Nadja Dornhöfer; Jens Einenkel; Grit Gesine Ruth Hiller; Christine E Brambs; Lars-Christian Horn
Journal:  J Cancer Res Clin Oncol       Date:  2020-09-11       Impact factor: 4.553
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.